CyTOF

BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma Biopsies

Retrieved on: 
Tuesday, October 4, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Washington University School of Medicine, TME, Cancer, Manuscript, Doctor of Philosophy, Sequence, CyTOF, WES, Research, Precision medicine, Economics, ITH, MD, Standard of care, Neoplasm, Cell Reports, RNA, Patient, Genetic heterogeneity, Biomarker, Tumor microenvironment, Washington University in St. Louis, RNA-Seq, Medical imaging, Medicine

Multiregional analyses revealed unexpected conservation of immune composition of the tumor microenvironment (TME) within each patient, with profound differences found among patients.

Key Points: 
  • Multiregional analyses revealed unexpected conservation of immune composition of the tumor microenvironment (TME) within each patient, with profound differences found among patients.
  • Further MxIF analysis showed striking spatial architectural heterogeneity among different regions of the same tumor, revealing the presence of diverse cellular neighborhoods.
  • BostonGene Tumor PortraitTM Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
  • Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Surge Raises $2.6M, Secures Exclusive Licensing Agreement with Stanford to Make Surgeries Safer

Retrieved on: 
Friday, September 23, 2022
Foch Hospital, Partner, Health, Boutique, Infection, Algorithm, Wilco, CyTOF, Stanford University School of Medicine, Risk, MD, Ferdinand Foch, StartX, Industry, Lists of diseases, Patient, Physician, Disease, Technology, Stanford University, Goal, Solution, Transparency (market), Doctor of Philosophy, Pasteur Institute, Dementia, SAN, Research, Ageing, Associate, Silicon, Hospital, Mortality, Hardware Club, Immune system, Plasma, AP-HP, Biotechnology, Medicine, Medical device, Pharmaceutical industry, Anesthesiology, Surge

SAN FRANCISCO, Sept. 23, 2022 /PRNewswire/ -- Biotech and medical AI innovator Surge announced a $2.6 million round co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley. Veteran angel investors, including Nicolas Godin, the COO/CFO of Cardiologs, also participated in the round. Surge was awarded the 2022 iLab grant, along with other non-dilutive grants to complete the fundraising.

Key Points: 
  • Surge was awarded the 2022 iLab grant, along with other non-dilutive grants to complete the fundraising.
  • In the summer of 2022, Surge also signed a research agreement with Stanford with the goal of developing biotech innovations.
  • The burden of complications is increasing as the population ages and the number of surgeries increases almost 5% per year (Transparency Market Research).
  • "We are proud to support Surge in its ambition to reduce the risk of postoperative complications.

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models

Retrieved on: 
Wednesday, September 7, 2022
Molecular imaging, PET, ADEM, Cancer, Research, Time of flight, Degenerative disease, Brain, Deoxycytidine kinase, Science, Multiple sclerosis, DCK, CyTOF, Pediatrics, DNA, EAE, Orphan drug, National, Immunology, GLOBE, National academy, Cytometry, Company, FDA, Stanford University, UCLA, MS, COVID-19, Optic neuritis, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Medical imaging

TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.

Key Points: 
  • TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.
  • Their results demonstrated that dCK activity is necessary for the development of clinical symptoms in both EAE models of MS.
  • Targeting dCK with TRE-515 limited disease severity when treatments were started prophylactically at disease induction or therapeutically after symptoms appear.
  • (2022), Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.

hC Bioscience Expands Leadership and Research & Development Teams

Retrieved on: 
Tuesday, September 6, 2022
Harvard Medical School, Massachusetts General Hospital, DMPK, Metabolomics, Patient, National Center for Advancing Translational Sciences, University, Cancer, Computer science, Biological engineering, Research, RNA transfection, Therapy, Â, Precision medicine, PTC Therapeutics, Mutation, CyTOF, Mechanical, HC, Savitribai Phule Pune University, Faculty, Broad Institute, Georgia Tech, B cell, Lists of diseases, Disease, GLOBE, Alnylam Pharmaceuticals, Hospital, Leadership, IP, MS, Weizmann Institute of Science, Drug discovery, Software, List of life sciences, Mechanical engineering, Proteomics, Virology, Management, Pharmaceutical industry, Technology, DRS

Landesman and Goel build on the addition of Dr. David Altreuter, who previously joined hC Bioscience as chief technology officer.

Key Points: 
  • Landesman and Goel build on the addition of Dr. David Altreuter, who previously joined hC Bioscience as chief technology officer.
  • Under their leadership, we continue to add members to our R&D team with expertise in tRNA biology, computational and formulation.
  • Prior to joining hC Bioscience, Dr. Landesman served as senior vice president of research and translational medicine at Karyopharm Therapeutics.
  • hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction.

Finding HIV's Sweet Spot

Retrieved on: 
Tuesday, July 5, 2022
Cell, Memory, Wistar Institute, National, Media contacts database, Communication, University of California, San Francisco, Tcell, Roan, Protein, Tissue, AIDS, Biomarker, Infection, Population, UM1, Center, Blood, HIV, SAN, Bias, Fucose, CyTOF, Moore v. Regents of the University of California, Technology, University, Sugar, Antibody, Doctor of Philosophy, Virus, Urology, Cell biology, Gladstone Institutes, HIV/AIDS, Research, Severe acute respiratory syndrome coronavirus 2, HIV/AIDS research, Multimedia, Lectin, Collection, Vaccine, Pharmaceutical industry, Antibiotics, ELife, William Ewart Gladstone

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- HIV researchers have long been trying to identify the specific cells that the virus prefers to infect and hide in. They know that HIV favors a special type of immune cells called memory CD4 T cells. But these cells come in many flavors, and it has been difficult to ascertain exactly what makes one type of memory CD4 T cell more attractive to HIV than another.

Key Points: 
  • Together, the scientists uncovered surprisingly different sugar patterns on different immune cells, and an intriguing interplay between HIV and the sugars coating CD4 Tcells.
  • The work also showcases a new technique for studying individual cells from large populations that could lead to a more detailed picture of cellular diversity.
  • Encouraged by this finding, the scientists next applied CyTOF-Lec to CD4 Tcells that they had first exposed to HIV in the lab.
  • To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.

Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, April 6, 2022
Disease, Company, LinkedIn, RSU, Letter, Microfluidics, Immunotherapy, Board, Biotechnology, Research, Health, Senior, Corporate development, Employment, Government, CyTOF, United, Twitter, Standard, GLOBE, Acceleration, Solution, YouTube, SAN, Nasdaq, Pharmaceutical industry, Fluidigm, Facebook

Each of Dr. Egholm, Mr. Kim, and Mr. Arfaei commenced employment with Standard BioTools on April 4, 2022.

Key Points: 
  • Each of Dr. Egholm, Mr. Kim, and Mr. Arfaei commenced employment with Standard BioTools on April 4, 2022.
  • Standard BioTools, previously known asFluidigm, is driven by a bold vision unleashing tools to accelerate breakthroughs in human health.
  • Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better.
  • Standard BioTools, the Standard BioTools logo, Fluidigm, theFluidigmlogo and CyTOF are trademarks and/or registered trademarks ofStandard BioToolsor its affiliates inthe United Statesand/or other countries.

Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

Retrieved on: 
Friday, April 1, 2022
Disease, Private Securities Litigation Reform Act, Regulation, Biomarker, LinkedIn, Microfluidics, Transaction, Marketing, Forward-looking statement, Immunotherapy, Viking Global Investors, Growth, Coronavirus, Board, Centerview Partners, Â, Paul, Weiss, Rifkind, Wharton & Garrison, SEC, Biotechnology, Research, Cancer, Health, Failure, U.S. Securities and Exchange Commission, Communication, Jefferies Group, Professional corporation, Government, Quality of life, LLC, CyTOF, Industry, Technology, Director, Twitter, Disclosure, Nasdaq, Wilson Sonsini Goodrich & Rosati, GLOBE, Regulation Fair Disclosure, Eye, SAN, Annual report, FDA, Social media, Security (finance), Renewable energy, Financial adviser, Joseph C. Casdin, Vikings, Fluidigm, Facebook

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (Casdin) and Viking Global Investors LP (Viking).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (Casdin) and Viking Global Investors LP (Viking).
  • Under the terms of the agreement, Casdin and Viking will purchase $225 million in aggregate principal amount of convertible preferred shares.
  • Jefferies LLC is serving as financial advisor to Fluidigm and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal advisor.
  • Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries.

Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

Retrieved on: 
Tuesday, March 29, 2022
Disease, Bio-Rad Laboratories, Private Securities Litigation Reform Act, Regulation, Biomarker, LinkedIn, Microfluidics, Transaction, Marketing, Forward-looking statement, Immunotherapy, Coronavirus, Centerview Partners, Paul, Weiss, Rifkind, Wharton & Garrison, Witney, PerkinElmer, SEC, Biotechnology, Genomics, Research, Cancer, CEO, Health, Failure, U.S. Securities and Exchange Commission, Communication, Jefferies Group, Professional corporation, Government, CyTOF, Quality of life, LLC, Industry, Technology, Twitter, Disclosure, Doctor of Philosophy, Wilson Sonsini Goodrich & Rosati, Cell biology, Regulation Fair Disclosure, Annual report, FDA, Social media, Security (finance), Financial adviser, Risk management, Indiana University, Fluidigm, Facebook, Dionex, Affymetrix

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that it has entered into a support agreement with Caligan Partners LP ("Caligan"), Fluidigm’s current largest holder of common stock, under which Caligan has agreed to vote “FOR” all Fluidigm proposals related to the proposed strategic capital infusion transaction with Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”) at Fluidigm’s Special Meeting of Stockholders (“Special Meeting”), which has been adjourned and will reconvene on April 1, 2022.

Key Points: 
  • Centerview Partners LLC is serving as financial advisor to Casdin and Viking.
  • Legal advisors are Paul, Weiss, Rifkind, Wharton & Garrison LLP serving Casdin and Kirkland & Ellis LLP serving Viking.
  • Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy.
  • Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries.

Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution

Retrieved on: 
Monday, March 28, 2022
Private Securities Litigation Reform Act, Regulation, Biomarker, LinkedIn, Microfluidics, Transaction, Marketing, Forward-looking statement, Immunotherapy, Coronavirus, Centerview Partners, Paul, Weiss, Rifkind, Wharton & Garrison, SEC, Biotechnology, Research, Cancer, Health, Failure, U.S. Securities and Exchange Commission, Communication, Jefferies Group, Professional corporation, Government, Quality of life, LLC, CyTOF, Industry, Technology, Twitter, Disclosure, Wilson Sonsini Goodrich & Rosati, Regulation Fair Disclosure, Eye, Annual report, FDA, Social media, Disease, Security (finance), Financial adviser, Risk management, Vikings, Fluidigm, Facebook

SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into an agreement with Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”) modifying the provision of the proposed strategic capital infusion transaction that permitted Fluidigm to adjourn the Special Meeting of Stockholders (“Special Meeting”) to April 1, 2022, instead of the allowed aggregate of 20 business days. Importantly, the parties will terminate the purchase agreements if Fluidigm stockholders do not approve the matters presented at the Special Meeting.

Key Points: 
  • Legal advisors are Paul, Weiss, Rifkind, Wharton & Garrison LLP serving Casdin and Kirkland & Ellis LLP serving Viking.
  • Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy.
  • Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries.
  • Founded in 1999, Viking is a global investment management firm that manages approximately $48 billion of capital for its investors.

Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022

Retrieved on: 
Friday, March 25, 2022
Private Securities Litigation Reform Act, Regulation, Biomarker, LinkedIn, Microfluidics, Transaction, Marketing, Forward-looking statement, Immunotherapy, Growth, Coronavirus, Centerview Partners, Paul, Weiss, Rifkind, Wharton & Garrison, SEC, Biotechnology, Research, Cancer, Health, Failure, U.S. Securities and Exchange Commission, Communication, Jefferies Group, Professional corporation, Government, Quality of life, LLC, CyTOF, Industry, Technology, Twitter, Disclosure, Wilson Sonsini Goodrich & Rosati, Regulation Fair Disclosure, Eye, Annual report, FDA, Social media, Disease, Security (finance), Financial adviser, Risk management, Vikings, Fluidigm, Facebook

Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy.

Key Points: 
  • Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy.
  • Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries.
  • Such information may be deemed material information, and Fluidigm may use these channels to comply with its disclosure obligations under Regulation FD.
  • Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.